Exclusive Summary

• - Fully off-patent with broad generic entry; FDA-GMP plus TT offering enables rapid access across markets.
• - High, steady pediatric demand across AOM/sinusitis/CAP/bite wounds drives large recurring volumes.
• - Listed on WHO EML/EMLc and recommended by major guidelines (IDSA/AAP) as first-line or preferred/alternative therapy.
• - Pediatric dry suspension carries stability/palatability barriers, leaving supply gaps for high-quality products.
• - Mature generics typically deliver 70–90% price savings vs Augmentin, winning in tenders and retail.